Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pTVG-HP plasmid DNA vaccine
- Development stage
- Phase 2
- Lead developer
- Madison Vaccines
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The pTVG-HP plasmid DNA vaccine is designed to stimulate the host immune system by generating a cytotoxic T lymphocyte (CTL) response against prostatic acid phosphatase (PAP)-expressing cells. It is primarily used in the treatment of prostate cancer, particularly in combination with checkpoint inhibitors like pembrolizumab or nivolumab to enhance its efficacy.
- Brand names
- MVI-816MVI816MVI 816
- Other names
- PAP DNA vaccineprostatic acid phosphatase DNA vaccine
02
Targets
PAP (Prostatic acid phosphatase)
Beyond the preview
Go deeper on pTVG-HP plasmid DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pTVG-HP plasmid DNA vaccine.